Increasing evidence suggests that mesenchymal stem/stromal cells (MSCs) carrying specific mutations are at the origin of some sarcomas. We have reported that the deficiency of p53 alone or in combination with Rb (Rb À / À p53 À / À ) in adipose-derived MSCs (ASCs) promotes leiomyosarcoma-like tumors in vivo. Here, we hypothesized that the source of MSCs and/or the cell differentiation stage could determine the phenotype of sarcoma development. To investigate whether there is a link between the source of MSCs and sarcoma phenotype, we generated p53 À / À and Rb À / À p53 À / À MSCs from bone marrow (BM-MSCs). Both genotypes of BM-MSCs initiated leiomyosarcoma formation similar to p53
INTRODUCTION
Multipotent mesenchymal stromal/stem cells (MSCs) represent a rare cell population present in many tissues that constitute a source of mesodermic progenitors. 1 Increasing evidence suggests that MSCs might be the cell of origin or tumor-initiating cell capable of initiating sarcomagenesis, and several types of sarcomas have been modeled by inducing transformation of MSCs with different oncogenic events. 2, 3 Sarcomas comprise a heterogeneous group of malignant tumors of mesenchymal origin that were historically grouped as soft tissue sarcomas (STSs) and primary bone sarcomas. 4 Sarcomas are generally studied once the full transformation events have already occurred, and therefore, the mechanisms of transformation are not amenable to analysis with patient samples, highlighting the need to establish bona fide experimental models to recapitulate sarcomagenesis. The development of in vivo sarcoma models using MSCs will likely constitute an unprecedented system to assay more efficient and specific therapies.
Dismantling of cell cycle regulation is often associated with sarcoma development. 3 Indeed, alterations in Rb and p53 genes are the most common mutations found in sarcomas characterized by complex kariotypes (that is, osteosarcoma and leiomyosarcoma). 4 Furthermore, Li-Fraumeni syndrome, which is caused by germline p53 mutations, and patients with germline Rb mutations display a higher frequency of both osteosarcomas and STS. 4, 5 In addition, the inactivation of the cell cycle control and the accumulation of genomic instability have been associated with spontaneous transformation of mouse MSCs. [6] [7] [8] [9] Similarly, genetic targeting of p53 in mouse MSCs triggers a transformation program in mouse MSCs. [10] [11] [12] [13] p53 and Rb are master regulators of cell homeostasis controlling cell cycle, apoptosis, senescence, proliferation and differentiation. Regarding mesenchymal differentiation, p53 activation suppresses osteoblast differentiation by inhibiting the expression of Runx2.
14 Conversely, p53 deletion accelerates osteoblastic differentiation although impairs osteocyte terminal maturation. 15 In addition to osteoblastic differentiation, p53 also inhibits the adipogenic and smooth muscle differentiation programs by downregulating peroxisome proliferator-activated receptor g and myocardin, respectively. 16 On the other hand, Rb has been reported to regulate mesenchymal differentiation along different mesenchymal lineages, including osteoblastic, adipogenic and myogenic through the transcriptional regulation of several lineage-specific transcription factors. [17] [18] [19] [20] For instance, Rb deficiency seems to impair bone development in favor of adipogenic differentiation. 17, 19 Mouse models displaying specific inactivation of p53 alone or in combination with Rb in the osteoblastic lineage through Oxterixdriven Cre expression developed osteoarcomas. 21, 22 Similarly, another mouse model in which p53 and Rb were inactivated in early mesenchymal tissues of embryonic limb buds also resulted in sarcoma development; mainly osteosarcomas although the concurrent deletion of Rb led to an increased prevalence of poorly differentiated STS. 23 In contrast to these reports linking p53 and Rb deficiency with osteosarcoma development, we have previously reported that p53
À / À and p53 À / À Rb À / À adiposederived MSCs (ASCs) give rise to leiomyosarcoma-like tumors in immunodeficient mice, and in no case histopathological features of osteosarcoma were observed. 13 Here, we hypothesize that there are two yet unexplored main factors potentially influencing the sarcoma phenotype, explaining at least in part, these differences between previous studies: (i) the distinct tissue source of the transformed MSCs and (ii) the different developmental stage along a particular mesenchymal lineage of the target cell in which transforming mutations arise. In order to address these two issues, MSCs were obtained from adipose tissue and bone marrow (BM) from p53 loxP/loxP and/or Rb loxP/loxP mice, and after Cre-mediated p53/Rb depletion, the tumorigenic potential of (i) p53
À / À MSCderived osteogenic progenitors was compared. Our data show that both p53
À / À and Rb À / À p53 À / À undifferentiated BM-MSC and ASCs initiate leiomyosarcoma. On the other hand, the inactivation of Rb and p53 in BM-MSC-derived osteogenic progenitors give rise to osteosarcoma-like tumors serially transplantable in immunodeficient mice. In contrast, Rb and p53 deficiency in ASC-derived osteogenic progenitors fails to promote sarcomagenesis. These data indicate that: (i) the differentiation stage of the MSCs imposes the phenotype of in vivo sarcoma development, (ii) the osteogenic progenitors differentiated from MSCs from distinct tissue sources do not necessarily exhibit similar transformation potential and (iii) BM-MSC-derived osteogenic progenitors rather than undifferentiated BM-MSCs, undifferentiated ASCs or ASC-derived osteogenic progenitors, seem to be the cell of origin for osteosarcoma development, at least when the cell cycle regulators Rb and p53 are deregulated.
RESULTS

p53
À / À and Rb À / À BM-MSCs were generated by excision of loxP sequences using Cre-recombinaseexpressing adenoviral vectors (Ad-CMV-Cre; Figure 1a ). Depletion of Rb and/or p53 in BM-MSCs was confirmed by genomic PCR (Figure 1b ) and western blot ( Figure 1c ). As expected, the expression of both Rb and p53 was increased on treatment with the topoisomerase I inhibitor campthotecin. BM-MSC cultures, similar to ASC cultures 13 showed typical mesenchymal surface antigen phenotype regardless of the genotype (Supplementary Figure S1A) . Functionally, p53
À / À , and especially Rb
BM-MSCs displayed a reduced adipogenic differentiation potential whereas the osteogenic capacity was enhanced in Rb Figure S1B) . Figure 1d ). Histological analysis classified these tumors as leiomyosarcomas-like tumors as they displayed key features of these smooth muscle-related tumors such as fascicles of cells intersecting at B901, elongated cells showing hiperchromatosis and pleomorfism in nuclei and isolated multinucleated giant cells. More importantly, p53
À / À and Rb À / À p53 À / À -derived tumors stained positive for smooth muscle-specific markers such as a-smooth muscle actin and caldesmon but were negative for skeletal muscle markers such as myosin (Figure 1e ). Together, p53
À / À and Rb Figure S2 ). This suggests that at least in the context of deregulation of the cell cycle regulators Rb and p53, the tissue source of undifferentiated MSC does not seem to determine the phenotype of sarcoma development in vivo.
To further characterize these experimentally induced leiomyosarcomas, primary tumors derived from p53
BM-MSCs were mechanically disaggregated and placed back in MSC culture conditions to establish immortalized cell lines (TBM-p53-1 to -3 and TBM-Rbp53-1 to -3). As expected, these tumor-derived cell lines remained deficient for p53 and Rb (Supplementary Figure S3A) and displayed identical morphology and immunophenotype to the parental BM-MSCs (data not shown). To investigate their tumorigenic potential, one of these ex vivoestablished cell lines were inoculated subcutaneously into secondary immunodeficient mice. All mice transplanted with either TBMp53 or TBMRbp53 cell lines developed tumors with a 100% penetrance and a much shorter latency period (B2 weeks) than the primary tumors (Supplementary Figure S3B) . Histopathological analysis of these tumors revealed that they retained the morphology and phenotype of leiomyosarcoma, including the expression of the smooth muscle actin and caldesmon (Supplementary Figure S3C ). These data demonstrate that the leiomyosarcoma tumors can be serially transplanted, indicating the presence of leiomyosarcoma-initiating cells within the p53 À / À and Rb
Gene expression analysis supports that p53-or Rbp53 deficiency in both BM-MSCs and ASCs promotes muscle-associated sarcomagenesis Regardless the tissue of origin (BM or fat), p53
À / À and Rb À / À p53 À / À -deficient MSCs initiate leiomyosarcoma in vivo, as confirmed by histology analysis (Figure 1e and Supplementary Figure S2 ). We then undertook gene expression profiling in primary p53
À / À and Rb Figure 2a and Supplementary Figure S4) . We next compared the gene expression signature of tumoral Tp53 cells derived from p53 À / À ASC vs p53 À / À BM-MSCs and found that they shared 41-62% of the genes differentially expressed (Figure 2b ). Similar overlap (39-58%) was found between the TRbp53 derived from Rb (Figure 2b ). This large overlay in the Finally, in order to gain insights into the signaling pathways that may be contributing to the development of leiomyosarcoma, we selected those genes commonly altered in Tp53 and TRbp53 cells that were associated with leiomyosarcoma by the IPA software. We found few genes exclusively altered in either Tp53 or TRbp53 cells (Figure 2c ). In contrast, the majority of genes were commonly altered in both Tp53 and TRbp53 cells (Figure 2c ), affecting key signaling pathways such as nuclear factor-kB pathway, phosphatase and tensin homolog signaling, interleukin-8 signaling and phosphatidylinositol 3 kinase/v-akt murine thymoma viral oncogene homolog 1 signaling (Figure 2c) . Therefore, the deregulation of these signaling pathways could be on the basis of the leiomyosarcoma pathogenesis in our experimental tumoral models.
Depletion of Rb and p53 in BM-MSC osteogenic derivatives leads to osteosarcoma development in vivo The tissue source of MSC does not seem to determine the phenotype of sarcoma development in vivo as suggested by the Table 1 . In vivo tumor formation ability of Wt, p53 À / À and Rb À / À p53 À / À ASCs/BM-MSCs and their derived tumors Tp53 and TRbp53 were compared with wt-ASC/BM-MSC and analyzed using the IPA software. IPA software-based data mining selected those genes differentially expressed and classified as associated with sarcomas. As it can be observed, all the genes differentially expressed were associated with leiomyosarcoma or other forms of muscle-derived sarcoma rather than sarcomas affecting other tissues, further confirming molecularly the leiomyosarcoma diagnosis regardless the source of the MSCs. (b) Venn diagrams representing the number of genes differentially expressed between Tp53 (left) and TRbp53 (right) tumor-derived cells and wt ASC or wt BM-MSCs. As many as 40-62% of the differentially expressed genes between tumoral MSCs and wt MSCs were common for ASCs and BM-MSCs, further confirming that the tissue source of MSC does not seem crucial in determining the phenotype of sarcoma development in vivo. (c) Scheme provided by IPA software specifically showing genes related to leiomyosarcoma development commonly or uniquely altered in Tp53 and TRbp53 as compared with wt MSCs (light/dark gray color correspond to down/upregulated gene expression). Nuclear factor (NF)-kB, phosphatase and tensin homolog (PTEN), phosphatidylinositol 3 kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT) and interleukin (IL)-8 signaling pathways are the most commonly altered routes in both Tp53 and TRbp53.
Influence of the BM-MSC stage of differentiation in sarcoma development R Rubio et al fact that Rb and p53 deficiency in undifferentiated ASC or BMMSCs give rise to the same tumor leiomyosarcoma. However, we hypothesized that the cell of origin for osteosarcomas could be an osteogenic lineage-committed progenitor cell rather than undifferentiated MSCs, and that the same oncogenic events might trigger different sarcoma phenotype depending on the differentiation/developmental stage of the MSCs being targeted. Thus, to analyze whether the BM-MSC/ASC differentiation stage may define the sarcoma phenotype, Rb loxP/loxP p53 loxP/loxP BM-MSCs/ ASCs were induced to differentiate toward the osteogenic lineage and both Rb and p53 were excised using Ad-CMV-Cre at different stages (day 0 (BM/ASC-Rbp53-Undiff cells), day 2 (BM/ASC-Rbp53-2Days cells), day 5 (BM/ASC-Rbp53-5Days cells) and day 10 (BM/ ASC-Rbp53-10Days cells)) along the osteogenic differentiation (Figure 3a) .
Depletion of Rb and p53 in undifferentiated BM-MSCs/ASCs and their osteogenic derivatives was confirmed by genomic PCR (Figure 3b ). Gradual in vitro osteogenic differentiation was monitored by quantitative reverse transcriptase-PCR analysis for several master osteogenic-specific factors such as osterix, BMP4, osteopontin, collagen type I and osteocalcin ( Figure 3c ). Similarly, proper osteogenic differentiation was functionally confirmed through the detection of osteogenicassociated calcium deposition by Alizarin red staining (Figure 3d ).
The tumorigenic potential of Rb and p53 depletion after 0, 2, 5 and 10 days of osteogenic differentiation was assessed by subcutaneous inoculation into NOD/SCID IL2Rg À / À mice. All Rb À / À p53 À / À BM-MSCs initiated tumors in vivo regardless their stage of differentiation with similar incidence (between 70% and 80%) and latency (ranging from 62 to 68 days; Table 2 and Figure 4a ). As expected, BM-Rbp53-Undiff cells initiated leiomyosarcoma-like tumors (Figures 1 and 4b) . However, tumors formed by BM-Rbp53-2Days, BM-Rbp53-5Days or BM-Rbp53-10Days cells consistently displayed clear osteosarcoma histological features including widespread areas of eosinophilic osteoid material containing cells embedded into the matrix as well as some areas of well-formed bone (Figure 4b ).
To determine whether these experimentally induced osteosarcomas can be serially transplanted, primary tumors formed from BM-Rbp53-2Days or BM-Rbp53-10Days cells as well as from BMRbp53-Undiff cells were mechanically disaggregated and placed back in MSC culture conditions to establish immortalized cell lines (TBM-Rbp53-2Days, TBM-Rbp53-10Days and TBM-Rbp53-Undiff). As expected, these tumor-derived cell lines remained deficient for Rb and p53 (Supplementary Figure S5A) . All the cell lines were able to generate tumors in vivo with a 100% penetrance and with a short latency period of 18-35 days (Supplementary Figure S5B) . Histopathological analysis of the secondary tumors generated from TBM-Rbp53-2Days and TBM-Rbp53-10Days revealed that they retained the main features of primary osteosarcomas including the presence of large areas of osteoid matrix whereas the secondary tumors derived from TBM-Rbp53-Undiff retained the leiomyosarcoma phenotype (Supplementary Figure S5B ). These data demonstrate that the osteosarcoma-like phenotype can be serially transplanted, indicating the presence of osteosarcoma-initiating cells within the Rb
Remarkably, Rb and p53 depletion in more committed osteogenic derivatives formed osteosarcoma-like tumors with more differentiated structures than in less differentiated osteogenic derivatives (Figure 4b) . Thus, osteosarcomas formed by BMRbp53-2Days cells or BM-Rbp53-5Days presented areas of osteoid matrix that became much denser in tumors formed by BM-Rbp53-10Days cells where areas of immature well-formed bone were eventually commonly developed (Figure 4b ). This observation is supported by the quantification of osteoid areas in randomly taken pictures from three different tumors of each condition. The presence of osteoid matrix in tumors developed from BM-Rbp53-10Days cells was twofold larger than in the tumors formed by BM-Rbp53-2Days or BM-Rbp53-5Days cells (Figure 4c) . Furthermore, the early osteogenic transcription factor osterix was specifically upregulated in the tumoral cell lines TBM-Rbp53-2Days and TBM-Rbp53-5Days whereas the late osteogenic marker osteocalcin was exclusively upregulated in the tumoral cell line TBM-Rbp53-10Days, indicating a higher degree of differentiation (Figure 4d) . Altogether, these data suggest that the differentiation stage of BM-MSCs imposes the phenotype of in vivo sarcoma development.
On the other hand, none of the Rb À / À p53 À / À ASC-derived osteogenic progenitors developed tumors when inoculated into NOD/SCID IL2Rg À / À mice ( Table 2 ) and only the ASC-Rbp53-Undiff cells gave rise to leiomyosarcoma-like tumors in vivo (Table 2 and Supplementary Figure S2) . These data indicate that the osteogenic progenitors differentiated from MSCs from distinct tissue sources do not necessarily exhibit similar transformation potential, and that BM-MSC-derived osteogenic progenitors rather than undifferentiated BM-MSCs, undifferentiated ASCs or ASCderived osteogenic progenitors, seem to be the cell of origin for osteosarcoma development, at least when the cell cycle regulators Rb and p53 are depleted.
Gene expression analysis supports that Rb and p53 inactivation in BM-MSCs but not ASC-derived osteogenic progenitors promotes osteosarcoma development To deepen our molecular understanding about the different tumor formation ability of BM-MSC-and ASC-derived osteogenic progenitors, we undertook gene expression profiling in BM-and ASC-Rbp53-10Days cells as well as in the ex vivo-derived tumoral TBM-Rbp53-10Days cells. IPA analysis of the lists of genes differentially expressed as compared with wt controls (wt-ASCs or wt-BM-MSCs) showed that the ASC-Rbp53-10Days cells were mainly associated with muscle-related sarcomas despite osteogenic priming (Figure 5a and Supplementary Figure S6) , similarly to ASC-Rbp53-Undiff cells (Figure 2a) . However, although IPA analysis showed a poor selection of genes related with sarcomas in BM-Rbp53-10Days it revealed many genes associated with bone cancer and osteosarcoma in TBM-Rbp53-10Days tumoral cells (Figure 5a and Supplementary Figure S6) , confirming the histological diagnosis of these tumors.
The gene expression signature of ASC-Rbp53-10Days and BM-Rbp53-10Days cells displayed an overlap of 27-29% (Figure 5b ), which is much lower than that observed between the tumors developed from the corresponding undifferentiated cells (Figure 2b ). This different gene expression signature between ASC-Rbp53-10Days and BM-Rbp53-10Days cells might partially explain the distinct tumor formation ability of the BM-MSC-and ASC-derived osteogenic progenitors. Using the IPA software, the signaling pathways and upstream regulators signaling associated with the group of genes specifically altered in ASC-Rbp53-10Days cells (left column) and in BM-Rbp53-10Days cells (right column) were analyzed (Figure 5c ). The pathways and upstream regulators signaling most significantly altered in the ASCs-Rbp53-10Days cells are mainly related with cell cycle control and DNA repair, whereas many of those altered in the BM-Rbp53-10Days cells are related to cell fate signaling, including several pathways involved in osteogenic differentiation and/or osteosarcoma development, including wingless-type MMTV integration site family-b-catenin, bone morphogenetic protein-transforming growth factor-b or calcium signaling pathways. 24 Although alterations in cell cycle regulation are common in osteosarcoma, the lack of alteration in wingless-type MMTV integration site family/b-catenin or bone morphogenetic proteintransforming growth factor-b signaling pathways, which are highly related to osteosarcoma development could partially Influence of the BM-MSC stage of differentiation in sarcoma development R Rubio et al explain the inability to initiate osteosarcoma of Rb-and p53-deficient ASC-derived progenitors.
DISCUSSION
Increasing evidence suggests that MSCs carrying specific mutations may be at the origin of sarcomas. Accordingly, modeling sarcomagenesis using MSCs is becoming an active area of research in an attempt to develop better sarcoma models to deepen our understanding about the cellular and molecular mechanisms underlying sarcoma initiation and pathogenesis. 2, 3 Mutations that contribute to tumoral transformation often disrupt cellular growth/survival by dismantling cell cycle checkpoints, and alterations in cell cycle regulators are frequent in sarcomas. In fact, we have recently reported that the deficiency of p53 alone or in combination with Rb (Rb À / À p53 À / À ) in ASCs promotes leiomyosarcoma-like tumors in vivo. However, to what extent the source of MSCs and the MSC differentiation stage influence the phenotype of sarcoma development remain to be elucidated.
In order to address these issues, the tumorigenic potential of The potential MSC origin of leiomyosarcoma is supported by a differentiation-based microRNA study. 25 Similarly, the deficiency of p53 and Rb in dermal MSCs was associated with the formation Influence of the BM-MSC stage of differentiation in sarcoma development R Rubio et al of pleomorphic STS. 26 In this study, 33% of the STS developed in the p53 loxP/loxP mice treated with Cre-expressing adenovectors were classified as pleomorphic leiomyosarcomas. In other mouse models in which mutations are restricted to muscle, p53 deficiency cooperated with oncogenic K-RAS to induce the formation of high-grade sarcomas with myofibroblastic differentiation. 27 Similarly, the deficiency in p53 and Rb has also been linked to leiomyosarcoma development in mouse ovaries. 28 Altogether, p53 and Rb deficiency in undifferentiated MSCs of different tissue origin imposes leiomyosarcoma development. The analysis of gene expression signatures in primary p53
À / À and Rb À / À p53 À / À BM-MSCs and ASCs as well as in their ex vivoestablished tumoral cell lines (Tp53 and TRbp53) showed a large overlap between BM and fat models and supported that Rb and p53 deficiency is associated with muscle-associated sarcomagenesis, regardless the tissue origin of the MSCs (Figures 2a and b) . Using IPA software, we selected those genes commonly altered in Tp53 and TRbp53 cells that were defined in public databases as associated with leiomyosarcoma (Figure 2c) . A high proportion of genes (40-60%) were commonly altered in both Tp53 and TRbp53 cells affecting key signaling pathways such as nuclear factor-kB pathway, phosphatase and tensin homolog signaling, interleukin-8 signaling and phosphatidylinositol 3 kinase/v-akt murine thymoma viral oncogene homolog 1 signaling. Interestingly, it has been reported that phosphatase and tensin homolog and v-akt murine thymoma viral oncogene homolog 1-mammalian target of rapamycin pathways have a critical role in the development of leiomyosarcomas. 29 Despite being well-established cancer-related pathways, the nuclear factor-kB and interleukin-8 signaling pathways remain unexplored in leiomyosarcoma. Therefore, the deregulation of these signaling pathways could be on the basis of the leiomyosarcoma pathogenesis in our experimental tumoral models. To analyze whether the differentiation stage may impose the sarcoma phenotype, BM-MSCs were induced to differentiate toward the osteogenic lineage and both p53 and Rb were excised using Cre-expressing adenovectors at different stages (day 2, 5 and 10) along osteogenic differentiation. Opposite to undifferentiated Rb
À / À BM-MSCderived osteogenic progenitors developed osteosarcoma-like tumors. Importantly, the longer the MSCs were allowed to differentiate toward osteogenic lineage the more differentiated osteosarcomas developed (Figures 4b-d) . Moreover, primary osteosarcomas were capable of reproducing the tumor phenotype in a secondary transplantation round, suggesting the presence of osteosarcoma-initiating cells. These data suggest that the osteogenic differentiation stage of BM-MSCs imposes the phenotype of in vivo sarcoma development, and that BM-MSC-derived osteogenic progenitors rather than undifferentiated BM-MSCs may represent the cell of origin in osteosarcoma. Our results are in line with previous reported mouse models in which p53 and Rb were specifically inactivated in the osteoblastic lineage by expressing Cre-recombinase under the regulation of the Osterix1 promoter. 21, 22 In these studies, osteosarcoma development was dependent on the loss of p53 and a concomitant loss of Rb accelerated tumorogenesis. Similarly, other mouse models in which p53 and Rb were inactivated in early mesenchymal tissues of embryonic limb buds after the expression of Cre-recombinase under the regulation of the Prx1 promoter also resulted in osteosarcoma development although the concurrent deletion of Rb led to an increased prevalence of poorly differentiated STS 23 and hibernomas. 17 However, the interpretation of sarcomagenesis models based on early mesenchymal tissue become somehow complicated given that the majority of human STS affects adults. The absence of a promoter capable of specifically driving Cre-recombinase expression in adult undifferentiated MSC poses a challenge for using similar mouse models to determine which tumor phenotype results on in vivo-specific inactivation of p53 and Rb in adult undifferentiated MSC. However, our ex vivo Rb À / À p53 À / À model has successfully allowed to compare the sarcoma phenotype on inactivation of p53 and Rb both in undifferentiated MSCs and in MSC-derived osteogenic progenitors. Importantly, although Rb and p53 inactivation in undifferentiated BM-MSCs did not initiate osteosarcoma, it cannot be ruled out that alternative mutations could induce osteosarcoma development in undifferentiated BM-MSCs. For instance, aneuploidization and the genomic loss of CDKN2A/p16 in BM-MSCs 8, 9 or the expression of c-MYC in p16
INK4A À / À p19 ARF À / À BM-MSCs resulted in osteosarcoma development. 30 Importantly, it has been reported that loss of functional INK4A/ARF locus has a critical role in the development of human osteosarcoma. 31, 32 Thus, CDKN2A/p16 could be altering the differentiation programs of undifferentiated MSCs. In this line, in the c-MYC-p16
the cell population presenting a higher ability to form osteosarcoma has lost the adipogenic potential in favor of the osteogenic potential, suggesting that the cell of origin for osteosarcoma may be a MSC population that have lost/reduced the adipogenic potential. Accordingly, our in vitro differentiation data support a reduced adipogenic differentiation coupled to an increased osteogenic potential of Rb Figure S1B) .
Interestingly, the development of osteosarcoma-like tumors occurs when Rb and p53 are targeted specifically in BM-MSC osteogenic derivatives as demonstrated by the fact that Rb À / À p53 À / À ASC-derived osteogenic derivatives did not develop sarcoma when inoculated into NOD/SCID IL2Rg À / À mice, indicating that the osteogenic progenitors differentiated Figure 5 . Gene expression profiling supports the osteosarcoma histological diagnosis of TBM-Rbp53-10Days tumors and reveals significant differences between BM-and ASC-Rbp53-10Days cells. (a) Genes differentially expressed (P-value o0.05; expression 42-fold up or down) in ASC-Rbp53-10Days, BM-Rbp53-10Days and TBMRbp53-10Days cells as compared with wt-ASC/BM-MSC were analyzed using the IPA software. IPA-based data mining selected those genes differentially expressed and classified as associated with sarcomas. Although ASC-Rbp53-10Days are related to muscle-derived sarcomas despite the osteogenic priming TBM-Rbp53-10Days tumor cells are associated with osteosarcoma. (b) Venn diagrams representing the number of genes differentially expressed between ASC-Rbp53-10Days or BM-Rbp53-10Days and wt ASC or wt BM-MSCs. After the osteogenic priming of the Rb À / À p53 À / À ASCs and BM-MSCs, the percentage of overlapping genes was B28%, much lower than tumors developed from the corresponding undifferentiated cells (B40-60%, Figure 2b ). (c) List of the most significantly modulated pathways and upstream regulators signaling generated with the genes specifically altered in ASC-Rbp53-10Days cells (left column) and BM-Rbp53-10Days cells (right column).
Influence of the BM-MSC stage of differentiation in sarcoma development R Rubio et al from MSCs from distinct tissue sources do not necessarily exhibit similar transformation potential. Accordingly, the gene expression signature of Rb À / À p53 À / À BM-MSC and ASC-derived osteogenic progenitors is considerably different with only B28% overlap (Figure 5b ). The osteosarcoma-related wingless-type MMTV integration site family/b-catenin and bone morphogenetic protein-transforming growth factor-b pathways are associated with the group of genes altered in BM-Rbp53-10Days cells but not in ASC-Rbp53-10Days cells, likely contributing to the different sarcomagenic potential 24 ( Figure 5c ). This distinct potential may be closely related to the differences revealed in the in vivo differentiation potential of MSCs derived from BM and other tissue sources. 33 These leiomyosarcoma/osteosarcoma models based on p53 and Rb depletion in undifferentiated MSC or MSC-derived osteogenic progenitors make us to speculate, in a global context, that a particular set of oncogenic mutations may impose one sarcoma phenotype or other, depending on the differentiation stage partially influenced by the tissue source.
Our data based on ex vivo MSCs extends our current knowledge about the cell of origin, the influence of the source and the differentiation stage of MSCs, and p53 and Rb deficiency in the phenotype of in vivo sarcoma development. In summary, we show that: (i) p53 deficiency is sufficient to transform both BM-MSCs and ASCs; (ii) Rb deficiency on its own is not sufficient to transform MSCs, but it potentiates sarcomagenesis induced by p53 inactivation; (iii) both Rb À / À p53 À / À undifferentiated BM-MSCs and ASCs initiate leiomyosarcoma in vivo; (iv) the osteogenic differentiation stage of BM-MSCs influences the phenotype of in vivo sarcoma development; (v) the cell of origin of osteosarcoma seems to be a BM-MSC-derived osteogenic progenitor rather than undifferentiated BM-MSCs, undifferentiated ASCs or ASC-derived osteogenic progenitors.
MATERIALS AND METHODS
Generation of mutant MSCs
MSCs were obtained from adipose tissue from gonadal, retroperitoneal and subcutaneous depots (ASCs) as previously described 11, 13 and from BM (BM-MSCs) of Friend leukemia virus B background mice bearing alleles for either p53, Rb or both genes flanked by LoxP sites. 13, 34 BM cells were flushed from the BM using a syringe with complete MSC growth medium (Dulbecco's modified Eagle's medium-advanced, 10% fetal bovine serum, 1% Pen/Strep and 1% Glutamax, all from Gibco, Carlsbad, CA, USA). The cell suspension obtained was passed through a 70 mm nylon filter (Becton Dickinson Biosciences, San Jose, CA, USA), washed twice and seeded at a density of 25 Â 10 6 cells/cm 2 in MesenCult medium (Stem Cell Technologies, Vancouver, Canada) at 37 1C in a 5% CO 2 
Western blot
Western blotting analysis of whole-cell extracts of exponentially growing cells was performed as previously described 11 using as primary antibodies In vivo tumorigenic assay NOD/SCID IL2Rg À / À (NSG) mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed under specific pathogen-free conditions, fed ad libitum according to animal facilities guidelines, and used at 8 to 12 weeks old. 37 NSG mice were inoculated subcutaneously with 5 Â 10 6 mutant undifferentiated ASCs/BM-MSCs, 5 Â 10 6 p53 À / À Rb À / À ASC/BM-MSC-derived osteogenic progenitors or 2 Â 10 5 primary tumor-derived cells, according to the United Kingdom Coordinating Committee for Cancer Research guidelines for the welfare of animals in experimental cancer research. Animals were killed when tumors reached 1 cm 3 or 150 days after infusion. Latency and tumor incidence were represented using Kaplan-Meier curves. The log-rank test and the hazard ratio with the 95% confidence interval were used to estimate significant differences among groups. 38, 39 On tumor removal, half the tumor was mechanically disaggregated to establish ex vivo MSCtransformed cell lines as previously described. 11 The remaining portion of the tumor was used for immunohistopathology analysis. 40 Gene expression profiling Primary (wt, p53 À / À , Rb À / À p53 À / À and Rbp53-10Days) as well as tumoral (Tp53, TRbp53 and TRbp53-10Days) ASC and BM-MSCs were collected during the exponential cell growth and stabilized in RNA later (Ambion, Austin, TX, USA) solution until RNA extraction. RNA was isolated using the Agilent Total RNA Isolation Kit (Agilent Technologies, Palo Alto, CA, USA) and its quality checked in the Agilent 2100 Bioanalyzer. Total RNA samples were labeled with Cy3 using the Quick-Amp Labeling kit (Agilent Technologies) and hybridized with the Whole Mouse Genome Microarray (G4122F), following the manufacturer's instructions (Agilent Technologies). Each sample was labeled and hybridized as independent triplicates. 41 Primary data were examined using GeneSpring 11.0 software (Silicon Genetics, Redwood City, CA, USA). Gene expression in the control and experimental groups was compared. Only genes satisfying the threshold of P-value o0.05 and a fold change expression 42 were included and Influence of the BM-MSC stage of differentiation in sarcoma development R Rubio et al assigned as significant. Analysis of pathways significantly altered in the experimental groups was performed using the IPA software 8.0 (Ingenuity Systems, Inc., Redwood City, CA, USA). Microarray data have been deposited and are available at Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/geo/).
Immunohistopathology analysis
Tumor samples were fixed in formol, embedded in paraffin, cut into 4-mm sections, and stained with hematoxylin and eosin and a panel of specific primary antibodies (all from DakoCytomation, Glostrup, Denmark) against: Caldesmon (1:500 dilution), smooth muscle actin (1:50 dilution) and myosin (1:100 dilution). The secondary horseradish peroxidase-conjugated rabbit anti-immunoglobulin G antibody was used at 1:100 dilution for 30 min. The immunostaining was visualized using diaminobenzidine and counterstained with hematoxylin. All the washing steps were done in phosphate-buffered saline. 42 The degree of osteogenic differentiation in the tumors was quantified by analyzing 20 images ( Â 10 magnification) randomly taken from three different tumors of each experimental condition. The area of osteoid matrix was quantified as the percentage of 'osteoid matrix/total area' using the Image J software (NIH, Bethesda, MD, USA). The mean and s.d. of the percentage of osteoid area in each condition was calculated.
